Steroids Versus Non-steroidal Anti-inflammatory Drugs Following Glaucoma Surgery

Topical Steroids Versus Topical Non-steroidal Anti-inflammatory Drugs Following Ahmed Valve Glaucoma Drainage Device Surgery

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00956462

Enrollment

Registered

2009-08-11

Start date

2007-07-31

Completion date

2010-06-30

Last updated

2009-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Keywords

intraocular pressure, Ahmed valve, NSAIDS, steroids

Brief summary

This study aims to evaluate the eye pressure response to non-steroidal anti-inflammatory eye drops as compared to steroid eye drops following glaucoma surgery.

Detailed description

Glaucoma is a chronic disease of the eye which results in gradual loss of nerve fibres, resulting in visual loss. The mainstay of treatment is reduction of intraocular pressure (IOP), which has been shown to preserve vision, and glaucoma surgery aims to achieve this. One type of surgery involves insertion of a glaucoma drainage device (GDD). Following surgery steroid eye drops are commonly used in order to reduce the inflammation that occurs as a result of the surgery. However, a common side effect of steroid eye drops is a rise in eye pressure. Non-steroidal anti-inflammatory drugs (NSAID) eye drops do not have this side effect and are used as an alternative to steroids following other types of eye surgery. Use of NSAID drops following GDD surgery may result in improved eye pressure. This study aims to evaluate the eye pressure response to NSAID eye drops following GDD surgery.

Interventions

DRUGKetorolac (NSAID) versus Dexamethasone (steroid)

Topical NSAID versus topical steroid after implantation of glaucoma drainage device

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

30 Years to 85 Years

Healthy volunteers

Inclusion criteria

1. 18 - 85 years of age 2. Undergoing glaucoma drainage device surgery

Exclusion criteria

1. Unable to consent 2. Undergoing combined GDD and cataract surgery 3. Patients with conditions requiring additional anti-inflammatory medications e.g., uveitic glaucoma, previous corneal transplant 4. Patients with prior history of corneal ulceration 5. Breast-feeding (nursing) mothers 6. Pregnant or planning to become pregnant during the trial period 7. Allergic to Ketorolac Tromethamine, or had an allergic-type reaction to acetylsalicylic acid or other non-steroidal anti-inflammatory drugs used for pain relief or arthritis

Design outcomes

Primary

Measure	Time frame
Intraocular pressure	Six weeks

Countries

Canada

Contacts

Primary ContactGraham E Trope, Professor

Graham.Trope@uhn.on.ca416-603-5317

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026